Review



mouse dpp4 cd26 antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems mouse dpp4 cd26 antibody
    Mouse Dpp4 Cd26 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 59 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse dpp4 cd26 antibody/product/R&D Systems
    Average 93 stars, based on 59 article reviews
    mouse dpp4 cd26 antibody - by Bioz Stars, 2026-06
    93/100 stars

    Images



    Similar Products

    dota linagliptin he dpp4 targeted probe  (MedChemExpress)
    94
    MedChemExpress dota linagliptin he dpp4 targeted probe
    Dota Linagliptin He Dpp4 Targeted Probe, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dota linagliptin he dpp4 targeted probe/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    dota linagliptin he dpp4 targeted probe - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    gene exp dpp4 mm00494538 m1  (Thermo Fisher)
    89
    Thermo Fisher gene exp dpp4 mm00494538 m1
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Gene Exp Dpp4 Mm00494538 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp dpp4 mm00494538 m1/product/Thermo Fisher
    Average 89 stars, based on 1 article reviews
    gene exp dpp4 mm00494538 m1 - by Bioz Stars, 2026-06
    89/100 stars
    		  Buy from Supplier
    anthine based dpp4 inhibitor linagliptin  (MedChemExpress)
    94
    MedChemExpress anthine based dpp4 inhibitor linagliptin
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Anthine Based Dpp4 Inhibitor Linagliptin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anthine based dpp4 inhibitor linagliptin/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    anthine based dpp4 inhibitor linagliptin - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    mouse dpp4 cd26 antibody  (R&D Systems)
    93
    R&D Systems mouse dpp4 cd26 antibody
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Mouse Dpp4 Cd26 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse dpp4 cd26 antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    mouse dpp4 cd26 antibody - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    human dpp4 cd26 antibody  (R&D Systems)
    93
    R&D Systems human dpp4 cd26 antibody
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Human Dpp4 Cd26 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human dpp4 cd26 antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    human dpp4 cd26 antibody - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    human cd26  (Creative BioMart)
    90
    Creative BioMart human cd26
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Human Cd26, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd26/product/Creative BioMart
    Average 90 stars, based on 1 article reviews
    human cd26 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    stock concentration  (Creative BioMart)
    90
    Creative BioMart stock concentration
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Stock Concentration, supplied by Creative BioMart, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stock concentration/product/Creative BioMart
    Average 90 stars, based on 1 article reviews
    stock concentration - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    mouse anti dpp4 cd26  (Proteintech)
    93
    Proteintech mouse anti dpp4 cd26
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Mouse Anti Dpp4 Cd26, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti dpp4 cd26/product/Proteintech
    Average 93 stars, based on 1 article reviews
    mouse anti dpp4 cd26 - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    dpp4 activity assay kit  (Merck & Co)
    86
    Merck & Co dpp4 activity assay kit
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Dpp4 Activity Assay Kit, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dpp4 activity assay kit/product/Merck & Co
    Average 86 stars, based on 1 article reviews
    dpp4 activity assay kit - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    anti cd26  (Proteintech)
    94
    Proteintech anti cd26
    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or <t>Dpp4</t> in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.
    Anti Cd26, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd26/product/Proteintech
    Average 94 stars, based on 1 article reviews
    anti cd26 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or Dpp4 in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.

    Journal: The Journal of Clinical Endocrinology and Metabolism

    Article Title: HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression—A Translational Study

    doi: 10.1210/clinem/dgaf608

    Figure Lengend Snippet: A to F, Oral glucose tolerance test (OGTT) performed after rosuvastatin (0.2 mg) treatment once daily for 27 days. A, Rosuvastatin-treated mice exhibit lower 60- and 90-minute plasma glucose levels, but B, area under the curve (AUC) was unaffected for glucose. C, Rosuvastatin-treated mice exhibit higher 5- and 60-minute plasma glucagon-like peptide 1 (GLP-1) levels, but D, AUC was unaffected for GLP-1. E, Rosuvastatin-treated mice had higher insulin secretion; AUC is presented in F. G, Long-term administration of rosuvastatin had no effect on the number of L cells in the jejunum. H to J, Long-term administration of rosuvastatin had no effect on intestinal messenger RNA expression of Gcg , Gip , Pyy , Pcsk1 , or Dpp4 in the H, duodenum; I, jejunum; or J, ileum. K, Long-term administration of rosuvastatin had no effect on β-cell mass. All parameters were assessed in 10 mice per group. Data are presented as box and whisker plots showing the minimum and maximum values (bottom and top error bars), the first (bottom of the box) and third (top of the box) quartiles and the median (middle of the box), or as a line graph showing the mean ± SEM. * P less than .05; ** P less than .01; and *** P less than .001 compared with vehicle-treated mice.

    Article Snippet: RNA was reverse-transcribed using RevertAid First Strand complementary DNA synthesis kit (Thermo Scientific). qPCR for Dpp4 (Mm00494538_m1), Gip (Mm00433601_m1) Hmgcr (Mm01282499_m1), Proglucagon ( Gcg ; Mm01269055_m1), Pcsk1 (Mm00479023_m1), Pyy (Mm00520715_m1), and 2 housekeeping genes ( Hprt [Mm03024075_m1] and Tbp [Mm01277042_m1]) was performed using TaqMan Expression PCR Master Mix (Life Technologies) using the ABI Prism 7900 HT system (Applied Biosystems).

    Techniques: Clinical Proteomics, RNA Expression, Whisker Assay